The p53 signaling pathway in tumors with wild-type TP53 (TP53 WT) is commonly affected by amplification or overexpression of MDM2, and this was demonstrated to be a major driver across malignancies with different histological characteristics, including breast cancer, colorectal cancer, lung cancer, sarcoma, and melanoma13,14. This evidence concerns the gene TP53 and sarcoma.